BLUE - bluebird bio - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

262.8M

Cash

174.3M

Avg Qtr Burn

-69.37M

Short % of Float

28.26%

Insider Ownership

0.36%

Institutional Own.

58.97%

Qtr Updated

09/30/23

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
ZYNTEGLO (beti-cel) Details Beta thalessemia	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
SKYSONA (eli-cel) (Lenti-D) Details cerebral adrenoleukodystrophy	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
LYFGENIA (Lovo-cel) (LentiGlobin) (bb1111) Details Sickle cell disease	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ABECMA (ide-cel) (bb2121) Details Multiple myeloma	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Lovo-cel Details Sickle cell disease	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.